Table 1.

demographic and clinical features of the patients enrolled in this study

	N° of patients = 137
Mean age at Tx (years ± SD)	46.1 ± 12.86
Sex (M:F)	91:46
Lenght of post-Tx follow-up (months/range, median)	105.9 / 6.7–310.5
Tx Indications
Emphysema / Alpha1 antitrypsin Deficiency	27
Primary graft disfunction	4
Bronchiectasis / Cystic Fibrosis	26
Interstitial lung disease	52
Pulmonary hypertension / Ebstein’s disease/Eisenmenger Syndrome / Mounier-Kuhn Syndrome	25
Rare pulmonary conditions	3
Type of Tx
Single lung Tx	46
Double lung Tx	83
Heart and Lung Tx	8
Immunosuppression therapy
Cyclosporine	23
Tacrolimus	119
Azathioprine	15
Mycophenolate mofetil	88
Rapamycin	37
Prednisone	137
Extracorporeal photopheresis (ever)	39
Azitromycin (ever)	98
	Total of determination = 1943
Stable	796
CLAD	1147
BOS	838
RAS	309
BOS 0p	320
CLAD 1	412
CLAD 2	169
CLAD 3	246

CLAD chronic lung allograft dysfunction, BOS bronchiolitis obliterans syndrome, RAS restrictive allograft syndrome. BOS 0p according to published guidelines [6, 30–32] CLAD 1: includes both BOS1 and RAS patients with FEV1 80–65% + FVC < 80%; CLAD 2: includes both BOS2 and RAS patients with FEV1 64–50% + FVC < 80%; CLAD 3: includes both BOS3 and RAS patients with FEV1 < 50% + FVC < 80%